ABBOTT LABORATORIES

Texas Rep. Julie Johnson Sold Up to $30K Worth of Abbott Laboratories Stock

Abbott Laboratories (ABT): One of the Best Bargain Stocks to Buy in June

Abbott Laboratories (NYSE:ABT) is one of the Best Bargain Stocks to Buy in June. On June 12, BofA analyst Travis Steed reduced the firm’s price objective on the company’s stock to $102 from $120 and maintained a “Buy” rating on the shares. The analyst took a more conservative view on 2027 med-tech company estimates. This is because […]

Is Abbott (ABT) the Best Longevity Stock to Buy Now?

Abbott Laboratories (NYSE:ABT) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Abbott Laboratories (NYSE:ABT) announced new data showing that diabetic ketoacidosis, or DKA, “remains an important” but often undetected health concern for people with both Type 1 and Type 2 diabetes. The findings, shared at the American Diabetes […]

This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In

Abbott Laboratories (NYSE:ABT) is a deep value stock to invest in now. On June 3, Abbott Laboratories (NYSE:ABT) entered into an expanded agreement with MiniMed. The two are joining forces to commercialize dual glucose-ketone sensors for integration with MiniMed smart dosing systems. The monitoring sensors under commercialization are designed to enable real-time detection of rising […]

Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness

Abbott Laboratories (NYSE:ABT) secured European CE Mark approval for Libre Duo, described as the world's first dual glucose and ketone continuous monitoring sensor. The company presented new data at the American Diabetes Association's 2026 Scientific Sessions on diabetic ketoacidosis risk and outcomes from its Healthy Food Rx program for people with type 2 diabetes. The American Cancer Society reaffirmed Abbott's Cologuard and Cologuard Plus as preferred options in updated US colorectal...

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott Laboratories: A Better Than 5 Years Ago - But Still Not A Buy

Abbott (ABT) looks fairly valued after a 26% drop. See Q1 results, Exact Sciences deal impact, debt/EPS dilution risks, and dividend outlook. See more here.

New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around

Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term.

Abbott (ABT) Secures CE Mark for World’s First Dual Glucose‑Ketone Sensing Technology for Diabetes

Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks to buy with highest upside potential. Abbott Laboratories (NYSE:ABT) announced on May 27 that it has secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people with diabetes. The systems are branded as Libre Duo and Libre Duo 10 Day, and are specifically […]

Is It Time To Revisit Abbott Laboratories (ABT) After This Year’s Share Price Slump?

If you are wondering whether Abbott Laboratories at around US$91.07 is a bargain or a value trap, you will want to look closely at what the current valuation is really telling you. The stock has risen 3.7% over the past week and 8.0% over the past month, yet it remains down 26.7% year to date and down 30.3% over the last year, which raises fair questions about how sentiment and risk perception have shifted. Recent headlines have focused on Abbott Laboratories as a large healthcare player,...